These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33072776)

  • 1. The Launch of the European Patients' Academy on Therapeutic Innovation in the Netherlands: A Qualitative Multi-Stakeholder Analysis.
    van Rensen A; Voogdt-Pruis HR; Vroonland E
    Front Med (Lausanne); 2020; 7():558. PubMed ID: 33072776
    [No Abstract]   [Full Text] [Related]  

  • 2. The Role of EUPATI CH in Promoting Patient Involvement in Clinical Research: A Multi-Stakeholder Research Project.
    Sessa C; Schmid C; Tolotti A; Magnin A; Haerry D; Bonetti L; Klingmann I
    Front Med (Lausanne); 2021; 8():795659. PubMed ID: 35004770
    [No Abstract]   [Full Text] [Related]  

  • 3. EUPATI Guidance for Patient Involvement in Medicines Research and Development (R&D); Guidance for Pharmaceutical Industry-Led Medicines R&D.
    Warner K; See W; Haerry D; Klingmann I; Hunter A; May M
    Front Med (Lausanne); 2018; 5():270. PubMed ID: 30356834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EUPATI and Patients in Medicines Research and Development: Guidance for Patient Involvement in Ethical Review of Clinical Trials.
    Klingmann I; Heckenberg A; Warner K; Haerry D; Hunter A; May M; See W
    Front Med (Lausanne); 2018; 5():251. PubMed ID: 30246010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EUPATI and Patients in Medicines Research and Development: Guidance for Patient Involvement in Regulatory Processes.
    Haerry D; Landgraf C; Warner K; Hunter A; Klingmann I; May M; See W
    Front Med (Lausanne); 2018; 5():230. PubMed ID: 30175100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving Patient Involvement in the Lifecycle of Medicines: Insights From the EUPATI BE Survey.
    Grine L; Janssens R; van Overbeeke E; Derijcke D; Silva M; Delys B; Dusart I; Aertsen V; Mertens de Wilmars M; Robaczewska J; Stevens H
    Front Med (Lausanne); 2020; 7():36. PubMed ID: 32118020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health Technology Assessment.
    Hunter A; Facey K; Thomas V; Haerry D; Warner K; Klingmann I; May M; See W
    Front Med (Lausanne); 2018; 5():231. PubMed ID: 30238004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: The European Patients Academy on Therapeutic Innovation (EUPATI) Guidelines on Patient Involvement in Research and Development.
    Spindler P; Lima BS
    Front Med (Lausanne); 2018; 5():310. PubMed ID: 30467543
    [No Abstract]   [Full Text] [Related]  

  • 9. Co-creating with patients an impact framework across the medicine's life cycle: a qualitative study exploring patients' experiences of involvement in and perceptions of impact measures.
    Gorbenko O; Cavillon P; Giles RH; Kolarova T; Marks M; Cardone A; Bagga S; Nolan C
    Res Involv Engagem; 2022 Feb; 8(1):1. PubMed ID: 35109927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA.
    Janssens R; Russo S; van Overbeeke E; Whichello C; Harding S; Kübler J; Juhaeri J; Bywall KS; Comanescu A; Hueber A; Englbrecht M; Nikolenko N; Pravettoni G; Simoens S; Stevens H; Hermann R; Levitan B; Cleemput I; de Bekker-Grob E; Veldwijk J; Huys I
    Patient; 2019 Oct; 12(5):513-526. PubMed ID: 31222436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redispensing of medicines unused by patients: a qualitative study among stakeholders.
    Bekker CL; Gardarsdottir H; Egberts TC; Bouvy ML; van den Bemt BJ
    Int J Clin Pharm; 2017 Feb; 39(1):196-204. PubMed ID: 28070689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations.
    Hansen MB; Nørgaard LS; Hallgreen CE
    Ther Innov Regul Sci; 2019 Aug; ():2168479019864294. PubMed ID: 31390896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations.
    Hansen MB; Nørgaard LS; Hallgreen CE
    Ther Innov Regul Sci; 2020 May; 54(3):577-585. PubMed ID: 33301145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice.
    Janssens R; van Overbeeke E; Verswijvel L; Meeusen L; Coenegrachts C; Pauwels K; Dooms M; Stevens H; Simoens S; Huys I
    Front Med (Lausanne); 2018; 5():285. PubMed ID: 30364285
    [No Abstract]   [Full Text] [Related]  

  • 15. Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis.
    van Hoof M; Chinchilla K; Härmark L; Matos C; Inácio P; van Hunsel F
    Drug Saf; 2022 Oct; 45(10):1083-1098. PubMed ID: 36008634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy.
    Scheijmans FEV; Zomers ML; Fadaei S; Onrust MR; van der Graaf R; Delden JJMV; van der Pol WL; van Thiel GJMW
    BMC Health Serv Res; 2022 Nov; 22(1):1320. PubMed ID: 36333803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis.
    Olyaaeemanesh A; Jaafaripooyan E; Abdollahiasl A; Davari M; Mousavi SM; Delpasand M
    Health Res Policy Syst; 2021 Dec; 19(1):150. PubMed ID: 34949207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Civil society engagement in multi-stakeholder dialogue: a qualitative study exploring the opinions and perceptions of MeTA members.
    Buckland-Merrett GL; Kilkenny C; Reed T
    J Pharm Policy Pract; 2017; 10():5. PubMed ID: 28070340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ideal of biopsychosocial chronic care: how to make it real? A qualitative study among Dutch stakeholders.
    van Dijk-de Vries A; Moser A; Mertens VC; van der Linden J; van der Weijden T; van Eijk JT
    BMC Fam Pract; 2012 Mar; 13():14. PubMed ID: 22405260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Informing a European guidance framework on electronic informed consent in clinical research: a qualitative study.
    De Sutter E; Borry P; Huys I; Barbier L
    BMC Health Serv Res; 2023 Feb; 23(1):181. PubMed ID: 36810088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.